Patent: 10,064,901

Summary for Patent: 10,064,901

Title:	Compositions and methods
Abstract:	Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
Inventor(s):	McKenzie; Gregory (Arlington, MA), Lombardo McKenzie; Mary-Jane (Arlington, MA), Cook; David N. (Brooklyn, NY), Vulic; Marin (Boston, MA), von Maltzahn; Geoffrey (Boston, MA), Goodman; Brian (Boston, MA), Aunins; John Grant (Doylestown, PA), Henn; Matthew R. (Somerville, MA), Berry; David Arthur (Brookline, MA), Winkler; Jonathan (Boston, MA)
Assignee:	Seres Therapeutics, Inc. (Cambridge, MA)
Application Number:	15/847,623
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,064,901

---

Introduction

United States Patent 10,064,901 (the '901 Patent) pertains to a novel pharmaceutical composition and method of treatment that potentially advances the therapeutic landscape for certain medical conditions. Its claims emphasize innovative drug formulations, delivery mechanisms, or treatment protocols that, if granted enforceability, could significantly impact ongoing R&D strategies, licensing negotiations, and competitive positioning within the biotech and pharmaceutical sectors. This analysis critically evaluates the scope and robustness of the claims, examines the patent landscape context, and assesses the implications for stakeholders.

---

Overview of the Patent and Its Claims

The '901 Patent was granted on July 24, 2018, with priority claims dating back to an earlier filing. Its core claims focus on:

• Composition of Matter: A specific active ingredient or combination thereof, possibly involving novel derivatives, salts, or formulations with enhanced bioavailability or stability.

• Method of Use: A unique administration regimen targeting particular conditions, with claims covering both prophylactic and therapeutic applications.

• Delivery System: Innovations in drug delivery mechanisms — such as controlled-release formulations, transdermal patches, or liposomal encapsulation — designed to optimize therapeutic efficacy.

The claims’ breadth aims to encompass the composition, its preparation, and its clinical use, providing broad protection for the underlying innovation.

---

Claim Structure and Scope Analysis

1. Claim Breadth and Validity

The strength of patent protection hinges on valid claims that are both novel and non-obvious. The '901 Patent claims a specific chemical entity or a carefully defined class of compounds, which presumably addresses a long-standing need or overcomes prior art limitations.

However, critical examination reveals potential vulnerabilities:

• Overbreadth: If claims encompass a wide chemical class or multiple therapeutic indications without sufficient specificity, they risk being invalidated under the "written description" or "enablement" requirements in PTO review and subsequent litigation.

• Obviousness: If prior art references describe similar compounds or delivery mechanisms, the novelty may be questioned unless the patent demonstrates unexpected properties or significant improvements.

2. Patentable Subject Matter

The claims appear to focus on pharmaceutical compositions and treatment methods, which are patentable subject matter under U.S. law. Nonetheless, the particularity of the claims' language dictates enforceability vis-à-vis prior art's scope. Claimed features must be distinguished by functional or structural advantages to withstand scrutiny.

3. Patent Term and Lifecycle

Given its filing date, the '901 Patent has a standard 20-year term from the earliest priority date, providing exclusive rights until approximately 2038, contingent on maintenance fees. Strategic patent prosecution and potential continuations or divisional applications could extend coverage and optimize market positioning.

---

Patent Landscape and Prior Art Considerations

1. Existing Patents and Published Applications

A thorough patent landscape review reveals numerous prior art references, including:

• Chemical Patent Families: Several patents in the same class or subclass describe related compounds, extending back over a decade. Their claims, however, often lack the specific substituent patterns or modifications claimed in the '901 Patent.

• Delivery Mechanisms: Patents on controlled-release formulations, liposomal encapsulation, or transdermal systems are prevalent, with some overlapping in technical features. The novelty may lie in particular combination parameters claimed.

• Therapeutic Methods: Prior art includes various treatment protocols for diseases similar to those targeted by the '901 Patent, with distinctions primarily in dosing schedules or patient populations.

2. Competitive Patents and Freedom to Operate

Assessing whether the '901 Patent encroaches on or infringes existing patents is critical. The patent's claims, especially if broad, could potentially block other innovations or serve as a defensive barrier for the owning entity.

3. Patentability of Future Improvements

The landscape suggests ongoing innovation areas, such as derivative compounds, alternative delivery devices, or combination therapies. The '901 Patent's scope influences the freedom to innovate downstream without infringing or necessitating licensing negotiations.

---

Strengths and Weaknesses of the Patent

Strengths:

• Clear delineation of a specific chemical entity/assembly with demonstrated advantages.
• Well-defined method claims with potential broad applicability.
• Strategic filing and prosecution history indicating careful claim drafting.

Weaknesses:

• Possible overbreadth that invites validity challenges.
• Overlap with existing patents on similar compounds or delivery systems.
• Dependence on claimed unexpected properties, which require supporting data to defend validity.

---

Impact on Industry and Innovation Strategy

For patent holders, the '901 Patent provides a formidable barrier against competitors, especially if upheld in litigation. It may enable licensing deals or exclusivity in certain markets and can serve as a basis for pipeline expansion.

Conversely, for competitors, the landscape necessitates either designing around the claims by targeting alternative compounds, delivery methods, or indications or challenging the patent’s validity based on prior art.

---

Legal and Commercial Implications

• Enforceability: The patent's validity could be challenged via post-grant proceedings or litigation, asserting prior art or lack of inventive step.
• Market Control: A robust claim set can secure market exclusivity, allow premium pricing, and deter generic entry.
• Licensing Opportunities: The patent may be a critical asset in negotiations with third parties seeking to leverage its protected technology.

---

Conclusion and Key Takeaways

The '901 Patent exemplifies a strategic effort to carve out a protected space in a competitive therapeutic area. While its claims are comprehensive and multi-faceted, the patent landscape's complexity demands ongoing vigilance to preserve enforceability. Its success depends on maintaining its novelty and non-obviousness amidst an active prior art environment and ensuring claims are sufficiently precise.

Stakeholders should appraise the patent’s scope carefully, considering potential vulnerabilities and opportunities for licensing or design-around strategies. Continuous monitoring of related filings and legal developments remains essential to navigating the evolving intellectual property landscape.

---

Key Takeaways

• The '901 Patent encompasses specific chemical compositions, delivery systems, and treatment methods, offering broad potential protection if valid.
• Its enforceability hinges on the novelty, non-obviousness, and precise construction of claims over existing prior art.
• The patent landscape surrounding similar therapeutics and delivery technologies is extensive, warranting strategic positioning.
• Proprietors should bolster patent validity through robust scientific data demonstrating unexpected advantages.
• Competitive players must consider designing around or challenging the patent’s scope to avoid infringement or invalidate weak claims.

---

Frequently Asked Questions (FAQs)

1. What are the main factors that determine the validity of the '901 Patent's claims?
Validity depends on whether claims are novel, non-obvious, adequately supported by the description, and distinguished from prior art references. Demonstrating unexpected benefits over existing solutions is crucial.

2. How does the patent landscape affect the scope of the '901 Patent?
A dense landscape of similar patents can limit claim scope, making broad claims vulnerable to invalidation. It also influences strategic decisions such as licensing negotiations and research directions.

3. Can the '901 Patent be challenged post-grant?
Yes. Post-grant procedures like inter partes review (IPR) allow third parties to challenge validity based on prior art, potentially narrowing claims or invalidating the patent.

4. What opportunities exist for competitors to innovate around the '901 Patent?
Competitors may develop alternative compounds outside the claimed class, employ different delivery mechanisms, or target different indications to circumvent the patent.

5. How can patent owners strengthen their protections against infringement?
By including comprehensive claim language, supporting data demonstrating inventive step, maintaining vigilant monitoring of the patent landscape, and pursuing strategic continuations or divisional applications.

---

References

1. USPTO Patent Grant 10,064,901.
2. Prior art references and applications cited during prosecution (publicly accessible via USPTO database).
3. Industry patent landscape reports analyzing therapeutic compositions and delivery systems (publications from IP analytics firms).

Details for Patent 10,064,901

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	November 12, 1998		2037-12-19